Best Colquitt County Grants for Nonprofits in Georgia

Building a global community of creative problem solvers, effective collaborators, and empathetic individuals through theatre

Our Mission and Goals

The Educational Theatre Foundation (ETF) is the philanthropic arm of the Educational Theatre Association (EdTA).

ETF advances the field of educational theatre by broadening representation and increasing access for all. ETF’s programs aim to support students, educators and the field at large by realizing three strategic goals:

• Subsidizing new, emerging, and underserved student theatre programs;
• Creating paths for theatre educators to develop new skills; and
• Commissioning research to showcase the value of a theatre education.

Educator & Program Grants

Giving school theatre programs a boost

The Thespian Growth & Excellence Fund is committed to supporting the ongoing development of theatre programs and the pursuit of excellence for educators, students, schools, and communities by offering a number of grants that assist in EdTA membership, teacher support, and programmatic resources for theatre in schools.

By the end of 2024, the Thespian Growth and Excellence Fund has awarded 349 grants to 276 schools, totaling $286,167 in assistance provided to school theatre programs, many at schools with Title 1 designations.

Equipment Upgrade (up to $5,000)

Can be awarded to help school theatre programs with large technical purchases that upgrade the resources available for theatrical use, such as lighting and sound equipment.

American Psychiatric Association Foundation

There is no health without mental health. The APA Foundation is working in your community to provide the support and resources we all need to prioritize mental wellbeing where you live, learn, work, worship, and play.

Backed by the medical expertise of the APA and industry-leading strategic partners, we administer community-changing programs, public education campaigns, grants, and awards aimed at increasing mental health literacy, connecting individuals to needed care, and shifting attitudes toward mental health.

Our Mission is to promote the mental health and well-being of individuals and communities. Our Vision is a mentally healthy nation for all – where we live, learn, work, worship, and play.

Diversity Leadership Fellowship

The Diversity Leadership Fellowship identifies and motivates minority psychiatry residents or those interested in minority and vulnerable populations to become well equipped to teach, administer, and provide culturally competent, evidence based mental health and substance abuse services to diverse minority groups and at-risk populations. These populations include—but are not limited to—American Indians/Native Alaskans, Asian Americans/Native Hawaiians/Native Pacific Islanders, Blacks/African Americans, Hispanics/Latinos, LGBTQ, and religious minorities. Program Benefits:

• Sponsorship to attend a minimum of four APA meetings:
  • Two APA Annual Meetings
  • Two Fellowship Forums
• Develop leadership skills in the field of psychiatry and advance understanding of the life experiences of racial ethnic minority communities
• Gain an understanding of APA/APAF Governance through observation and service on an APA Council, Committee, or APAF initiative
• Have the opportunity to sit on the APAF Board of Directors as a non-voting member (one Diversity Leadership fellow allowed)
• Cultivate a professional network with psychiatrists interested in minority mental health and services through exclusive events and engagements with APA leaders. Establish relationships and peer-mentorship with a diverse group of resident fellows with similar career interests and goals

Alkermes

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference in the way people manage these chronic diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.

Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.

Investigator Sponsored Studies Program

Alkermes seeks to support research designed and conducted by independent clinicians and scientists through our Investigator Sponsored Studies (ISS) program. Alkermes may occasionally announce a Request for Proposals (RFP) for research in clinical areas where gaps in data have been identified. 

The ISS research Alkermes supports must be based in the United States and is typically conducted by experienced researchers who have an established history of successfully completing research with independent funding. Alkermes can provide its marketed products to the ISS programs it supports. In addition, there may be financial support available, but please note that study budgets cannot exceed $300,000 (inclusive of overhead).

• ISS Areas of Interest
  • Sleep Disorders
  • Schizophrenia & Bipolar I Disorder
  • Schizophrenia

Alkermes

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders, including addiction, serious mental illness and sleep disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference in the way people manage these chronic diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.

Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.

Pathways APN Research Awards

The Alkermes Pathways Advanced Practice Nurse (APN) Research Awards™ program is designed to empower the advanced practice nursing community by offering funding opportunities that recognize their vital role in evidence-based care and the advancement of mental health research.

The Alkermes Pathways APN Research Awards provide opportunities for individual grants of up to $10,000 per project for licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic, and/or community health settings and are committed to advancing research in schizophrenia or bipolar I disorder.

Interface Health Foundation

Interface Health Foundation is a non-profit, 501c3 tax-exempt organization driven by a collective vision of positive change. In healthcare industry policy, understanding the intricate dynamics of funding and its impact on public access, quality, and cost remains paramount. IHF is dedicated to advancing analysis and research into the crossroads of healthcare industry policy, structural frameworks and affordability.

At IHF, our mission is clear: to empower and support student-led research endeavors that shed light on critical healthcare policy and structural issues affecting the public. Through our initiatives, we seek to foster a deeper understanding of the complex dynamics shaping the healthcare landscape.

Interface Health Foundation: Research Grant

Healthcare administrative grant award opportunities are highly competitive and allow candidates to stand out as they enter the job market. Through this IHF grant award, you will get the opportunity to pull together research and content on topics that aren't fully studied or publicized. Depending on the grant topic, some grantees will also have access to a preceptor who is an executive leader in the healthcare field. The preceptor will serve as a valuable resource to the grantee during the development of the research paper and beyond.

An example of a research topic is the impact of legislated acute care nurse staffing levels on the following: nursing professional job satisfaction, the patient experience, and the standard nursing quality indicators as part of nursing Magnet status accreditation.

Mary Kay Ash Foundation

Guided by Mary Kay Ash’s dream to enrich the lives of women everywhere, the Mary Kay Ash Foundation® raises and distributes funds to invest in breakthrough cancer research and clinical trials to find a cure for women-related cancers and ending domestic violence.

Since 1996, the Mary Kay Ash Foundation®, a 501(c)3 organization, has contributed more than $100 million to organizations aligned with its two-fold mission. In addition, the Foundation supports awareness initiatives, community outreach programs, and advocates for legislation to ensure women are healthy and safe. Through our global charitable foundations in Brazil, Canada, China and the United States, we are collectively making a deeper impact on the lives of women around the world.

Mary Kay Ash Foundation: Cancer Research Grant

The Mary Kay Ash Foundation is a non-profit public foundation, which focuses on funding research for innovative grants for translational research of cancers affecting women (ovarian, uterine, breast, endometrial or cervical cancer among others). Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Ultimately, such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. Each year the Foundation extends invitations to NCI designated cancer institutes and accredited medical schools to apply. Only one application is accepted per institution.

Grant proposals are reviewed by a Scientific Research Review Committee comprised of notable members of the American medical and scientific community. Grants are awarded up to $100,000 (combined direct and indirect costs) for a two-year period. The Foundation anticipates funding between 10 and 15 grants annually. 

Multiplex Platforms to Assess Indicators of Micronutrient Status, Inflammation and Infectious Disease

The Challenge

Although combined immunological measurement of several micronutrient biomarkers has been demonstrated, current methods still have important limitations. These include heterogeneity in the composition of standards and controls; inconsistent batch-to-batch performance of analyte-binding molecules; variable reactivity for some analytes, especially soluble transferrin receptor (sTfR); and a functional analytical range that is too narrow to cover the physiological values of some analytes, such as CRP. It would also be valuable to add bioindicators for vitamins B1, B2, B9 and B12, which may require binding molecules that recognize metabolites or proteins associated with deficiency, a specific vitamer (plasma methyl-tetrahydrofolate without reacting with folic acid), comparable reactivity across vitamers (several folate forms in red blood cells), or a specific carrier-protein form (holo-transcobalamin rather than apo-transcobalamin or haptocorrin for vitamin B12).

The improved assays must combine high analytical specificity, sensitivity and robustness with a functional analytical range matched to the physiological values expected in the target populations (women of reproductive age, including during pregnancy and lactation, preschool-age children and older adults). Assays must remain low-cost (no more than US$20 for all analytes measured in duplicate) and require very small sample volumes, preferably less than 10 µL of plasma or serum). The tests are intended for population surveillance rather than local clinical (point-of-care) use. They should be designed to run many samples in a single batch in a small number of national or regional reference laboratories. The goal is to reduce dependence on expensive, infrequent population surveys and on export of samples to specialized laboratories in high-income settings.

This challenge is structured around two alternatives, a minimum-scope approach and an optimistic-scope approach. Targets are aligned with the candidate Target Product Profile for this platform, and applicants will be held to the relevant performance, cost and instrument targets.

Multiplex Platforms to Assess Indicators of Micronutrient Status, Inflammation and Infectious Disease

The Challenge

Although combined immunological measurement of several micronutrient biomarkers has been demonstrated, current methods still have important limitations. These include heterogeneity in the composition of standards and controls; inconsistent batch-to-batch performance of analyte-binding molecules; variable reactivity for some analytes, especially soluble transferrin receptor (sTfR); and a functional analytical range that is too narrow to cover the physiological values of some analytes, such as CRP. It would also be valuable to add bioindicators for vitamins B1, B2, B9 and B12, which may require binding molecules that recognize metabolites or proteins associated with deficiency, a specific vitamer (plasma methyl-tetrahydrofolate without reacting with folic acid), comparable reactivity across vitamers (several folate forms in red blood cells), or a specific carrier-protein form (holo-transcobalamin rather than apo-transcobalamin or haptocorrin for vitamin B12).

The improved assays must combine high analytical specificity, sensitivity and robustness with a functional analytical range matched to the physiological values expected in the target populations (women of reproductive age, including during pregnancy and lactation, preschool-age children and older adults). Assays must remain low-cost (no more than US$20 for all analytes measured in duplicate) and require very small sample volumes, preferably less than 10 µL of plasma or serum). The tests are intended for population surveillance rather than local clinical (point-of-care) use. They should be designed to run many samples in a single batch in a small number of national or regional reference laboratories. The goal is to reduce dependence on expensive, infrequent population surveys and on export of samples to specialized laboratories in high-income settings.

This challenge is structured around two alternatives, a minimum-scope approach and an optimistic-scope approach. Targets are aligned with the candidate Target Product Profile for this platform, and applicants will be held to the relevant performance, cost and instrument targets.

Quality Improvement Grant Request for Proposals

Optimizing Maternal RSV Immunization Delivery: A Systems-Based Quality Improvement Initiative to Improve Uptake, Equity, and Newborn Outcomes

Pfizer, in collaboration with the Society for Maternal-Fetal Medicine (SMFM), is pleased to announce a competitive grant opportunity to support independent Quality Improvement (QI) initiatives focused on advancing maternal immunization, with a specific emphasis on Respiratory Syncytial Virus (RSV) vaccination during pregnancy.

This initiative builds upon insights generated from the Maternal Immunization Needs Assessment (MINA) project, a multi-stakeholder collaboration that identified persistent clinical, behavioral, and system-level gaps in the delivery and uptake of maternal vaccines.

We seek to fund projects that implement measurable, evidence-based interventions to improve real-world delivery of maternal RSV immunization across healthcare systems and care settings. Proposed initiatives should aim to optimize access, strengthen provider–patient communication training and tools, enhance care coordination, and address structural and behavioral barriers impacting vaccine uptake and equity.

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies. Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the specific gaps in clinical practice or care as outlined in the specific RFP.

For all QI grants, the applicant (and ultimately the grantee) will be solely responsible for the design, implementation, and conduct of the proposed initiative. Pfizer will have no involvement in project development, execution, or outcomes.

About the ASHFoundation

ASHFoundation supports innovators and sparks innovation in communication sciences. We give early support to promising students, researchers, and clinicians exploring bold ideas to transform the field and improve people's lives.

Frank R. Kleffner Lifetime Clinical Career Award

The Frank R. Kleffner Lifetime Clinical Career Award recognizes an individual’s outstanding contributions to communication sciences and disorders over a period of at least 20 years. The lifetime contribution may have been in clinical service, supervision or administration of clinical service, clinical research, or any other activity that has promoted clinical excellence.

The award is given in honor of Frank R. Kleffner, a former ASHFoundation president and former ASHA president, who worked tirelessly over his lifetime until his passing in 2015 to professionalize and expand the ASHFoundation’s charitable goals.

The awardee receives a commemorative art object with a recognition plaque.

Disabled Veterans National Foundation

The Disabled Veterans National Foundation (DVNF) was established in 2007 to support veterans facing challenges that traditional systems could not fully address. From its earliest days, DVNF has been focused on closing critical gaps in care and providing resources that help veterans rebuild their lives with dignity and stability.

Guided by this commitment, DVNF developed its Health & Comfort programs, offering emergency financial assistance, housing transition support, food assistance, comfort kits, and wellness initiatives. These programs are designed to meet veterans where they are and to provide practical solutions that restore hope and stability. Today, DVNF continues to grow as a trusted national nonprofit. Every day, our team works with a clear purpose: to change lives for the men and women who have served our country.

Homeless To Housing Program - Financial Assistance

DVNF is dedicated to assisting disabled and at-risk veterans in their transition from homelessness to permanent housing. Recognizing that securing a home is a significant milestone, DVNF understands that true stability is achieved when a house becomes a home, furnished with essential items that provide comfort and functionality. We help cover essential costs related to securing and creating comfortable housing for at-risk veterans.

The H2H Program offers comprehensive support to veterans by providing: Financial Assistance of up to $2,000 to cover essential costs related to securing permanent housing, such as security deposits and initial rent payments.

For Financial Assistance: Payments are processed through two payment cycles each month, around the 15th and 30th. If your payment is delayed beyond the expected date, a Promissory Note of Payment will be issued to the vendor, confirming our organization's responsibility and requesting that no penalties be applied to the applicant.

Better Food Policy Fund 

Since its inception, the Better Food Policy Fund has set its strategic direction in a participatory fashion. We are intentionally building capacity for engagement to ensure the Fund aligns with the needs of food policy council stakeholders.   

Thus far, the Fund has engaged 300+ food policy council stakeholders to help co-develop the Fund. We are immensely grateful for the individuals who helped shape the initial direction of this fund. We view this growing stakeholder audience as the people to whom the Fund’s governing body, the Independent Advisory Committee, is ultimately accountable.

Grantmaking

The Better Food Policy Fund invests in US-based food policy councils, empowering community and government collaboration for progressive food policy. We utilize participatory processes to enhance equity and redistribute power in the funding landscape. We seek to celebrate and uplift the work of food policy councils, and believe every food policy council is worthy of financial support.

We define “food policy councils” as councils, networks, coalitions, or other groups working across boundaries at the tribal, municipal, county, state, or regional level.  

We support actions aimed at ensuring an enabling environment for policy change, such as: 

• increasing levels of inclusive and equitable stakeholder engagement in public processes
• engaging systems thinking when tackling complex food system challenges
• facilitating collaboration with and across local government agencies and departments 
• developing or revising local policies and plans  

We define “better food policy” as practices, procedures, ordinances, laws, etc. of governing institutions which strengthen community-based food systems.

We define “civic collaboration” as people joining together at the intersection of community and government to address public issues.